Dermira, Inc. (NASDAQ:DERM) Ratings Summary on May 17, 2018

May 17, 2018 - By Nellie Rakes

Dermira, Inc. (NASDAQ:DERM) Corporate Logo
Big Money Sentiment decreased to 1.27 in Q4 2017. It has change of 0.76, from 2017Q3’s 2.03. The ratio dived due to Dermira, Inc. positioning: 16 sold and 35 reduced. 25 funds amassed positions and 40 increased positions. Investors holded 41.09 million in 2017Q3 but now own 38.81 million shares or 5.56% less.
Guggenheim Lc reported 0.01% of its capital in Dermira, Inc. (NASDAQ:DERM). Awm Investment Inc invested in 100,500 shs or 0.54% of the stock. International Grp Inc reported 0% stake. Services Automobile Association holds 0% or 22,268 shs. Abingworth Ltd Liability Partnership accumulated 1.41% or 70,000 shs. Goldman Sachs Inc invested in 0% or 167,590 shs. First Personal Fincl Services reported 707 shs. Nicholas Invest Ptnrs Lp has invested 0.17% in Dermira, Inc. (NASDAQ:DERM). Cubist Systematic Strategies Lc holds 14,314 shs. 367,592 are owned by Deutsche Comml Bank Ag. Barclays Public Ltd reported 11,045 shs. Private Capital Inc holds 35,000 shs or 0.34% of its capital. Moreover, Granite Point Cap Mgmt Ltd Partnership has 0.1% invested in Dermira, Inc. (NASDAQ:DERM) for 36,633 shs. Manufacturers Life Insur Com The has 29,513 shs for 0% of their capital. Metropolitan Life Insurance Company accumulated 0% or 12,912 shs.

Dermira, Inc. registered $1.01 million net activity with 0 insider purchases and 10 selling transactions since December 13, 2017. On Thursday, March 1 $12,658 worth of stock was sold by BAUER EUGENE A. $137,566 worth of Dermira, Inc. (NASDAQ:DERM) was sold by WIGGANS THOMAS G on Wednesday, December 13. On Tuesday, January 2 Cohen David E sold $16,818 worth of Dermira, Inc. (NASDAQ:DERM).

Dermira, Inc. (NASDAQ:DERM) Ratings Coverage

Total analysts of 5 have positions in Dermira (NASDAQ:DERM) as follows: 3 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 60%. Since December 5, 2017 according to StockzIntelligence Inc Dermira has 9 analyst reports. On Tuesday, December 12 Mizuho maintained Dermira, Inc. (NASDAQ:DERM) rating. Mizuho has “Buy” rating and $39.0 target. On Tuesday, December 5 the firm has “Buy” rating by Guggenheim given. On Thursday, May 3 the rating was maintained by Cantor Fitzgerald with “Buy”. On Wednesday, January 17 Leerink Swann maintained Dermira, Inc. (NASDAQ:DERM) with “Buy” rating. The stock rating was downgraded by Guggenheim to “Neutral” on Tuesday, March 6. On Monday, March 5 the firm earned “Hold” rating by Mizuho. On Thursday, February 22 the rating was maintained by Cantor Fitzgerald with “Buy”. On Friday, February 23 the company was maintained by Mizuho. Listed here are Dermira, Inc. (NASDAQ:DERM) PTs and latest ratings.

03/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0000 Maintain
06/03/2018 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Downgrade
05/03/2018 Broker: Mizuho Rating: Hold Downgrade
05/03/2018 Broker: Cowen & Co Rating: Buy New Target: $25.0
23/02/2018 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
22/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
17/01/2018 Broker: Leerink Swann Rating: Buy New Target: $48.0 Maintain
12/12/2017 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
05/12/2017 Broker: Guggenheim Rating: Buy Initiate

DERM touched $11.13 during the last trading session after $0.38 change.Dermira, Inc. has volume of 165,295 shares. Since May 17, 2017 DERM has declined 77.97% and is downtrending. The stock underperformed the S&P 500 by 89.52%.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States.The firm is worth $465.77 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.Currently it has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

For more Dermira, Inc. (NASDAQ:DERM) news posted briefly go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Christopher Horan Joins Dermira as Chief Technical Operations Officer” posted on April 19, 2018, “Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference” on May 01, 2018, “Dermira to Host Analyst & Investor Day on May 24, 2018” with a publish date: May 14, 2018, “Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update” and the last “Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” with publication date: May 08, 2018.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.